What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.
They turn cautious and prefer defensive bets
The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it
Shares of Glenmark Pharma, Granules India, Divi's Laboratories, Torrent Pharma, Lupin and Aurobindo Pharma, surged in the range of 2 per cent to 6 per cent in Monday's intra-day trade
Easing pricing pressures, complex generics uptick in the US, steady India/emerging-market growth potential booster shots
Street remains bullish on India prospects, regulatory headwinds for Goa site continue
The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year
Rerating on the cards; the domestic business is expected to outperform
Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing
Large part of gains in two years accrued to top companies in metals, IT, pharma and realty
Alembic Pharma and Dr Reddy's Labs plunged 12% and 11%, respectively in intra-day trade post their June quarter results
Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each
Since April, the index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50; Sun Pharma scales 4-year high
Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index
Cipla, Gland Pharma, JB Chemicals and Pharma, Max Healthcare, Neuland Lab and Apollo Hospital from BSE Healthcare index hit their respective record highs today
At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index
Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE
Despite the large economic impact of the Covid-19 pandemic, the markets have recovered sharply even though the performance among individual stocks has been quite polarised
Good momentum in US and domestic sales, along with Covid-19 treatment portfolio is already driving analysts to upgrade earnings estimates
The Indian pharmaceutical sector has also been going through a surge